Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Gilead Sciences (NASDAQ: GILD), and ...

Dr Vivienne Cox believes that carbohydrates and sweet treats were fuelling her body and keeping amyotrophic lateral sclerosis ...

Evaxion Biotech A/S, a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, launches an ...

Another biotech startup revealed plans Friday evening for an initial public offering, making it the sixth startup to list new ...

An office and lab property in Thousand Oaks has sold in an all-cash transaction. Los Angeles-based Alta West Partners and an ...

A rare-disease federal incentive program critical to biotech R&D is in jeopardy, writes Leslie Williams, president and CEO of ...

US-based financial services company Vanguard Group acquired shares worth Rs 998 crore in seven Indian companies via open market transactions on the NSE. Concurrently, Zurich-based UBS Group AG sold ...

A rather odd week in venture, as the biggest rounds were raised by greentech, business travel and charity startups. Of course ...

UBS sold holdings in Concord Biotech, Five Star Business Finance, IIFL Securities, and Marksans Pharma through block deals, ...

An early-stage biotech investor called YK Bioventures plans to raise $100 million, according to an SEC filing on Wednesday.

Slow enrollment in a key clinical trial has driven Genfit to rework the protocol to try to keep the study on track. | Slow ...